International Biotechnology Trust plc
Portfolio Update
The Board of International Biotechnology Trust plc (the "Company") notes that the portfolio company RespiVert Ltd has been sold to Centocor Ortho Biotech, Inc.
The Directors have changed the valuation of the Company's interest in RespiVert from £1.00m to £2.07m on a cost of £0.50m to reflect the terms of the deal. The upfront payment is recognised in full - £1.90m, the escrow payments are recognised at 50% of their value or £0.17m. This change in valuation will be included in the Company's net asset value ("NAV") from today and will be released to the market tomorrow. The increase to NAV per share in comparison to that released on Friday is 1.7p.
Enquiries:
Kate Bingham/David Pinniger
Telephone: 020 7412 7070
SV Life Sciences Managers LLP
Investment Manager
Rachael Nelson
For and on behalf of
BNP Paribas Secretarial Services Limited
Company Secretary
Telephone: 020 7410 3132
1 JUNE 2010